Prothena Corporation PLC (NASDAQ:PRTA) – Stock analysts at Oppenheimer Holdings lifted their FY2017 earnings per share estimates for Prothena Corporation PLC in a research note issued to investors on Thursday. Oppenheimer Holdings analyst J. Olson now expects that the biotechnology company will earn ($4.23) per share for the year, up from their prior forecast of ($4.54). Oppenheimer Holdings currently has a “Buy” rating and a $70.00 target price on the stock. Oppenheimer Holdings also issued estimates for Prothena Corporation PLC’s Q4 2017 earnings at ($1.40) EPS, FY2018 earnings at ($4.85) EPS, FY2019 earnings at ($4.20) EPS, FY2020 earnings at ($1.48) EPS and FY2021 earnings at ($1.04) EPS.
Other analysts also recently issued reports about the company. Deutsche Bank AG reaffirmed a “buy” rating on shares of Prothena Corporation PLC in a report on Sunday, October 1st. Jefferies Group LLC reaffirmed a “buy” rating and set a $100.00 price target on shares of Prothena Corporation PLC in a report on Monday, October 2nd. SunTrust Banks, Inc. reiterated a “buy” rating and set a $75.00 target price on shares of Prothena Corporation PLC in a research report on Monday, October 2nd. Royal Bank Of Canada reiterated a “buy” rating on shares of Prothena Corporation PLC in a research report on Friday, September 29th. Finally, BTIG Research cut their target price on Prothena Corporation PLC from $80.00 to $77.00 and set a “buy” rating on the stock in a research report on Friday, September 29th. One analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $78.58.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/15/fy2017-eps-estimates-for-prothena-corporation-plc-prta-increased-by-analyst.html.
Shares of Prothena Corporation PLC (NASDAQ:PRTA) opened at $56.13 on Monday. Prothena Corporation PLC has a fifty-two week low of $45.13 and a fifty-two week high of $70.00.
Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.04. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. Prothena Corporation PLC had a negative return on equity of 34.40% and a negative net margin of 562.19%. Prothena Corporation PLC’s revenue for the quarter was down 33.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.26) EPS.
In related news, insider Gene G. Kinney sold 2,800 shares of the business’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $70.00, for a total value of $196,000.00. Following the transaction, the insider now owns 5,593 shares in the company, valued at approximately $391,510. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tara Nickerson sold 17,500 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the transaction, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The disclosure for this sale can be found here. Insiders sold a total of 29,424 shares of company stock worth $1,922,787 in the last 90 days. 3.10% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the stock. Bank of Montreal Can increased its position in Prothena Corporation PLC by 6.7% in the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 117 shares during the period. Quantbot Technologies LP increased its position in Prothena Corporation PLC by 672.7% in the 2nd quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 1,628 shares during the period. Strs Ohio increased its position in Prothena Corporation PLC by 69.2% in the 3rd quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock valued at $142,000 after acquiring an additional 900 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Prothena Corporation PLC by 187.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 1,549 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in Prothena Corporation PLC in the 3rd quarter valued at approximately $206,000.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.